Asset Details
Do you wish to reserve the book?
Update on Novel Hormonal and Nonhormonal Male Contraceptive Development
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Update on Novel Hormonal and Nonhormonal Male Contraceptive Development
Do you wish to request the book?
Update on Novel Hormonal and Nonhormonal Male Contraceptive Development
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Update on Novel Hormonal and Nonhormonal Male Contraceptive Development
2021
Overview
Abstract
Background
The advent of new methods of male contraception would increase contraceptive options for men and women and advance male contraceptive agency. Pharmaceutical R&D for male contraception has been dormant since the 1990s. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969 and supports most ongoing hormonal male contraceptive development. Nonhormonal methods are in earlier stages of development.
Content
Several hormonal male contraceptive agents have entered clinical trials. Novel single agent products being evaluated include dimethandrolone undecanoate, 11β-methyl-nortestosterone dodecylcarbonate, and 7α-methyl-19-nortestosterone. A contraceptive efficacy trial of Nestorone®/testosterone gel is underway. Potential nonhormonal methods are at preclinical stages of development. Many nonhormonal male contraceptive targets that affect sperm production, sperm function, or sperm transport have been identified.
Summary
NICHD supports development of reversible male contraceptive agents. Other organizations such as the World Health Organization, the Population Council, and the Male Contraception Initiative are pursuing male contraceptive development, but industry involvement remains limited.
Publisher
Oxford University Press
Subject
/ Contraceptive Agents, Male - isolation & purification
/ Contraceptive Agents, Male - therapeutic use
/ Female
/ Hormonal Contraception - history
/ Hormonal Contraception - methods
/ Hormonal Contraception - trends
/ Humans
/ Male
/ National Institute of Child Health and Human Development (U.S.)
/ Sperm
